Log in

ASX:CDYCellmid Stock Price, Forecast & News

0.00 (0.00 %)
(As of 05/13/2020)
Today's Range
Now: A$0.19
50-Day Range
MA: A$0.18
52-Week Range
Now: A$0.19
Average VolumeN/A
Market Capitalization$17.87 million
P/E RatioN/A
Dividend YieldN/A
Cellmid Limited, a life sciences company, develops and commercializes diagnostic and therapeutic products for cancer and various chronic inflammatory conditions in Australia, the United States, and Japan. The company offers Midkine (MK) ELISA Kit, a cancer biomarker, and diagnostic and prognostic tool. It is also developing CAB102, a humanized monoclonal antibody for use in solid tumors; CAB101, a monoclonal antibody for the treatment of kidney injury, and inflammatory and fibrotic diseases; and CMK103, a recombinant human form of MK protein for use in cardiac ischemia. In addition, the company develops and sells over-the-counter products; and develops and markets a range of FGF5 inhibitor hair growth products under the evolis name. As of November 01, 2018, it operated 17 stores and through online, which offers the évolis professional products in the United States. Cellmid Limited is based in Sydney, Australia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.08 out of 5 stars

Industry, Sector and Symbol

Industry Biotechnology
Phone61 2 9221 6830



Sales & Book Value

Annual Sales$7.65 million
Cash FlowA$0.04 per share
Book ValueA$0.07 per share



Market Cap$17.87 million
Next Earnings DateN/A
OptionableNot Optionable

Receive CDY News and Ratings via Email

Sign-up to receive the latest news and ratings for CDY and its competitors with MarketBeat's FREE daily newsletter.

Cellmid (ASX:CDY) Frequently Asked Questions

How has Cellmid's stock been impacted by COVID-19 (Coronavirus)?

Cellmid's stock was trading at A$0.13 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CDY shares have increased by 45.1% and is now trading at A$0.19. View which stocks have been most impacted by Coronavirus.

How were Cellmid's earnings last quarter?

Cellmid Limited (ASX:CDY) issued its quarterly earnings data on Thursday, February, 21st. The company reported ($0.05) EPS for the quarter. View Cellmid's earnings history.

Has Cellmid been receiving favorable news coverage?

Headlines about CDY stock have trended neutral recently, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Cellmid earned a media sentiment score of 0.2 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news about Cellmid.

Who are some of Cellmid's key competitors?

Who are Cellmid's key executives?

Cellmid's management team includes the following people:
  • Ms. Maria Halasz, CEO, MD & Exec. Director
  • Mr. Koichiro Koike, Managing Director of Advangen Inc (Age 62)
  • Dr. Graham Robertson, Head of R&D
  • Mr. Lee Tamplin, Company Sec.

What is Cellmid's stock symbol?

Cellmid trades on the ASX under the ticker symbol "CDY."

What is Cellmid's stock price today?

One share of CDY stock can currently be purchased for approximately A$0.19.

How big of a company is Cellmid?

Cellmid has a market capitalization of $17.87 million and generates $7.65 million in revenue each year.

What is Cellmid's official website?

The official website for Cellmid is www.cellmid.com.au.

How can I contact Cellmid?

The company can be reached via phone at 61 2 9221 6830.

This page was last updated on 7/11/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.